Aeterna Zentaris Gmbh

Zentaris Gmbh

Zentaris Ag

Asta Medica, Aktiengesellschaft

Ziophram Oncology, Inc.

Ae Zentaris Gmbh

Æterna Zentaris Gmbh

Eckhard Günther

Peter Emig

Bernd Nickel

Bernhard Kutscher

Dietmar Reichert

Jürgen Schmidt

Matthias Gerlach

Silke Baasner

Peter Schmidt

Gerald Bacher

Herbert Sindermann

Jurgen Engel

Irene Seipelt

Eckhard Claus

Ulf R Rapp

Beate Aue

Ludmilla Wixler

Silke Basner

Thomas Beckers

Emmanuel Polymeropoulos

Thomas Reissmann

Tilmann Schuster

Jürgen Engel

Klaus Paulini

Michael Bernd

Ronald Kühne

Peter Romeis

Guillaume Le Baut

Istvan Szelenyi

Kay Brune

Michael Teifel

Babette Aicher

Gilbert Mueller

Michael Czech

Lars Blumenstein

Olaf Schaefer

Arvid Söderhäll

Peter Ernig

Jens-Peter Wulf

Julien Defaux

Pascal Marchand

Gilbert MÜLLER

The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II.  One such preferred alkylphosphocholine is perifosine.

Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II.  One such preferred alkylphosphocholine is perifosine.

The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II. 

Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals

The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II.  A particularly effective treatment includes administering a combination of perifosine and capecitabine.

Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations. 

Pyridopyrazines and the use thereof as kinase inhibitors

The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.

Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)

The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors. 

Indole derivatives and their use as medicament

The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of a compound of the invention. Hormone-dependent cancers that can be treated with the methods of the invention include prostate cancer, breast cancer, ovarian cancer, endometrial cancer, and pancreatic cancer. Non-malignant indications which can be treated by the methods of the invention include benign prostate hyperplasia (BPH), endometriosis, acne, polycystic ovarian disease, dysmenorrhea, precocious puberty, and uterine fibroids and other leiomyomas.

Methods of treatment using novel LHRH antagonists having improved solubility properties

The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.

Indolyl-3-glyoxylic acid derivatives having antitumor action

Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs)

The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors 

Indole derivatives and their use as medicaments

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations 

The invention relates to novel N-substituted indolyl-3-glyoxylamides of the general formula I, their preparation and use as medicaments, in particular for the treatment of tumors 

N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation

Growing community of inventors

Maintal, Germany

Eckhard Günther